Comparing SG&A Expenses: Perrigo Company plc vs Soleno Therapeutics, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the world of pharmaceuticals and therapeutics, understanding the financial health of a company is crucial. This chart provides a fascinating comparison of Selling, General, and Administrative (SG&A) expenses between Perrigo Company plc and Soleno Therapeutics, Inc. over the past decade.

Perrigo Company plc: A Steady Climb

Perrigo, a global leader in over-the-counter health and wellness solutions, has seen its SG&A expenses grow by approximately 89% from 2014 to 2023. This steady increase reflects Perrigo's strategic investments in marketing and administration to maintain its competitive edge.

Soleno Therapeutics, Inc.: A Different Path

In contrast, Soleno Therapeutics, a company focused on rare disease treatments, has experienced a more modest rise in SG&A expenses, increasing by about 362% over the same period. This growth, while significant, is indicative of Soleno's targeted approach in a niche market.

Insights and Implications

The divergent trends in SG&A expenses highlight the distinct strategies of these companies. While Perrigo's broad market approach necessitates higher administrative costs, Soleno's focused strategy allows for more controlled spending.